Looking ahead to targeting macrophages by CAR T- or NK-cells in blood cancers.

IF 4.6 2区医学 Q1 PHARMACOLOGY & PHARMACY

Expert Opinion on Therapeutic Targets Pub Date : 2024-09-05 DOI:10.1080/14728222.2024.2400075

David Kegyes, Paul Alexandru Milea, Andreea-Isabella Mazga, Adrian-Bogdan Tigu, Madalina Nistor, Diana Cenariu, Radu Tomai, Sanda Buruiana, Hermann Einsele, Alina Daniela Tănase, Ciprian Tomuleasa

{"title":"Looking ahead to targeting macrophages by CAR T- or NK-cells in blood cancers.","authors":"David Kegyes, Paul Alexandru Milea, Andreea-Isabella Mazga, Adrian-Bogdan Tigu, Madalina Nistor, Diana Cenariu, Radu Tomai, Sanda Buruiana, Hermann Einsele, Alina Daniela Tănase, Ciprian Tomuleasa","doi":"10.1080/14728222.2024.2400075","DOIUrl":null,"url":null,"abstract":"Introduction: The bone marrow microenvironment (BME) is critical for healthy hematopoiesis and is often disrupted in hematologic malignancies. Tumor-associated macrophages (TAMs) are a major cell type in the tumor microenvironment (TME) and play a significant role in tumor growth and progression. Targeting TAMs and modulating their polarization is a promising strategy for cancer therapy.Areas covered: In this review, we discuss the importance of TME and different multiple possible targets to modulate immunosuppressive TAMs such as: CD123, Sphingosine 1-Phosphate Receptors, CD19/CD1d, CCR4/CCL22, CSF1R (CD115), CD24, CD40, B7 family proteins, MARCO, CD47, CD163, CD204, CD206 and folate receptors.Expert opinion: Innovative approaches to combat the immunosuppressive milieu of the tumor microenvironment in hematologic malignancies are of high clinical significance and may lead to increased survival, improved quality of life, and decreased toxicity of cancer therapies. Standard procedures will likely involve a combination of CAR T/NK-cell therapies with other treatments, leading to more comprehensive cancer care.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Therapeutic Targets","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14728222.2024.2400075","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: The bone marrow microenvironment (BME) is critical for healthy hematopoiesis and is often disrupted in hematologic malignancies. Tumor-associated macrophages (TAMs) are a major cell type in the tumor microenvironment (TME) and play a significant role in tumor growth and progression. Targeting TAMs and modulating their polarization is a promising strategy for cancer therapy.

Areas covered: In this review, we discuss the importance of TME and different multiple possible targets to modulate immunosuppressive TAMs such as: CD123, Sphingosine 1-Phosphate Receptors, CD19/CD1d, CCR4/CCL22, CSF1R (CD115), CD24, CD40, B7 family proteins, MARCO, CD47, CD163, CD204, CD206 and folate receptors.

Expert opinion: Innovative approaches to combat the immunosuppressive milieu of the tumor microenvironment in hematologic malignancies are of high clinical significance and may lead to increased survival, improved quality of life, and decreased toxicity of cancer therapies. Standard procedures will likely involve a combination of CAR T/NK-cell therapies with other treatments, leading to more comprehensive cancer care.

查看原文本刊更多论文

展望在血癌中使用 CAR T 细胞或 NK 细胞靶向巨噬细胞。

简介骨髓微环境（BME）对健康的造血至关重要，但在血液恶性肿瘤中却经常遭到破坏。肿瘤相关巨噬细胞（TAMs）是肿瘤微环境（TME）中的主要细胞类型，在肿瘤生长和进展中发挥着重要作用。靶向 TAMs 并调节其极化是一种很有前景的癌症治疗策略：在这篇综述中，我们讨论了TME的重要性以及调节免疫抑制性TAMs的多种可能靶点，如CD123、Sphingosos等：CD123、1-磷酸卵磷脂受体、CD19/CD1d、CCR4/CCL22、CSF1R (CD115)、CD24、CD40、B7家族蛋白、MARCO、CD47、CD163、CD204、CD206和叶酸受体：抗击血液恶性肿瘤微环境免疫抑制环境的创新方法具有重要的临床意义，可提高生存率、改善生活质量并降低癌症疗法的毒性。标准程序可能会将 CAR T/NK 细胞疗法与其他疗法相结合，从而提供更全面的癌症治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Opinion on Therapeutic Targets 医学-药学

CiteScore

8.90

自引率

1.70%

发文量

审稿时长

3 months

期刊介绍： The journal evaluates molecules, signalling pathways, receptors and other therapeutic targets and their potential as candidates for drug development. Articles in this journal focus on the molecular level and early preclinical studies. Articles should not include clinical information including specific drugs and clinical trials. The Editors welcome: Reviews covering novel disease targets at the molecular level and information on early preclinical studies and their implications for future drug development. Articles should not include clinical information including specific drugs and clinical trials. Original research papers reporting results of target selection and validation studies and basic mechanism of action studies for investigative and marketed drugs. The audience consists of scientists, managers and decision makers in the pharmaceutical industry, academic researchers working in the field of molecular medicine and others closely involved in R&D.

文献相关原料

公司名称	产品信息	采购帮参考价格